Liu Xiaowei, Lee Sangil, Lohse Christine M, Hardy Cassandra T, Campbell Ronna L
Department of Emergency Medicine, The First Affiliated Hospital of China Medical University, Liaoning, Shenyang, China; Department of Emergency Medicine, Mayo Clinic, Rochester, Minn.
Department of Emergency Medicine, The University of Iowa Carver College of Medicine, Iowa City, Iowa.
J Allergy Clin Immunol Pract. 2020 Apr;8(4):1230-1238. doi: 10.1016/j.jaip.2019.10.027. Epub 2019 Nov 6.
Biphasic reaction rates and potential associated risk factors are not well understood.
To evaluate biphasic reaction rates and associated risk factors.
We prospectively enrolled patients with anaphylaxis at 2 Midwestern academic emergency departments (EDs). We gathered data using patient and ED provider surveys and a structured health record review. Biphasic reaction rates and clinically significant biphasic reaction rates, defined as recurrent reactions that met anaphylaxis diagnostic criteria or were treated with epinephrine, were calculated. Characteristics associated with biphasic reactions were assessed with logistic regression and reported with odds ratios (ORs) and 95% CIs.
Of 430 ED anaphylaxis visits, 31 (7.2%) patients had biphasic reactions; 22 (5.1%) had clinically significant biphasic reactions. The median time from anaphylaxis onset to first epinephrine dose was longer for patients with biphasic (78 minutes) than uniphasic courses (45 minutes) (P = .005). A biphasic course was associated with an ED setting of first epinephrine dose (OR, 3.72; 95% CI, 1.36-10.14) and a delay of more than 30 minutes from symptom onset to first epinephrine dose (OR, 3.39; 95% CI, 1.13-10.18), and was inversely associated with arrival by ambulance (OR, 0.18; 95% CI, 0.05-0.61). A clinically significant biphasic reaction was associated with an ED setting of first epinephrine dose (OR, 3.32; 95% CI, 1.08-10.25) and inversely associated with arrival by ambulance (OR, 0.08; 95% CI, 0.01-0.61).
Biphasic reactions and clinically significant biphasic reactions occurred in 7.2% and 5.1% of ED anaphylaxis patients, respectively. Delayed epinephrine administration was associated with biphasic reactions.
双相反应率及潜在相关危险因素尚未得到充分了解。
评估双相反应率及相关危险因素。
我们前瞻性纳入了美国中西部2家学术性急诊科的过敏反应患者。我们通过患者及急诊科医护人员调查问卷以及结构化健康记录回顾来收集数据。计算双相反应率及具有临床意义的双相反应率,具有临床意义的双相反应率定义为符合过敏反应诊断标准或接受肾上腺素治疗的复发性反应。采用逻辑回归评估与双相反应相关的特征,并以比值比(OR)和95%置信区间(CI)进行报告。
在430例急诊科过敏反应就诊患者中,31例(7.2%)出现双相反应;22例(5.1%)出现具有临床意义的双相反应。双相反应患者从过敏反应发作到首次使用肾上腺素剂量的中位时间(78分钟)长于单相病程患者(45分钟)(P = 0.005)。双相病程与首次肾上腺素剂量在急诊科给予有关(OR,3.72;95% CI,1.36 - 10.14)以及从症状发作到首次肾上腺素剂量延迟超过30分钟有关(OR,3.39;95% CI,1.13 - 10.18),并且与乘坐救护车到达呈负相关(OR,0.18;95% CI,0.05 - 0.61)。具有临床意义的双相反应与首次肾上腺素剂量在急诊科给予有关(OR,3.32;95% CI,1.08 - 10.25),并且与乘坐救护车到达呈负相关(OR,0.08;95% CI,0.01 - 0.61)。
双相反应和具有临床意义的双相反应分别发生在7.2%和5.1%的急诊科过敏反应患者中。肾上腺素给药延迟与双相反应有关。